The glucagon-like peptide-1 (GLP-1) receptor agonist drug class, used to manage type 2 diabetes, is also proving to be highly effective for the treatment of obesity and has the potential to meet this growing need
Plus, there is a published double-blind, placebo controlled study using this supplement
SURMOUNT-1: Tirzepatide 15 mg, the generational leap of 2022 SURMOUNT-1 (Jastreboff et al., NEJM 2022, PMID 35658024) randomized 2,539 obese adults without diabetes to tirzepatide 5, 10, or 15 mg/week or placebo over 72 weeks
Research peptide suppliers offer 60-80% cost reduction
[DOI] [PubMed] [Google Scholar] 18.Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Jr., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., et al
This might look like bloating, differences in bowel movements, and increased gas